Literature DB >> 25916346

A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements.

Franco Franchignoni1, Jessica Mandrioli2, Andrea Giordano3, Salvatore Ferro4.   

Abstract

Our objective was to verify and expand previous evidence of psychometric inadequacies in the ALSFRS-R, in a different sample of subjects suffering from ALS. Since 2009, a prospective registry records all incident cases of ALS in Emilia Romagna Region, Italy (4.4 million inhabitants) referred to its 17 neurological departments. For each patient, demographic and clinical information is collected by the physician in charge, including compilation of the ALSFRS-R at each clinical follow-up. Results showed that a confirmatory factor analysis on the three-factor model previously found (bulbar, motor, respiratory function) showed a good fit. Rasch analysis on the whole scale showed the need to collapse some rating categories, confirmed the multidimensionality of the ALSFRS-R, and demonstrated the presence of differential item functioning between patients with spinal versus bulbar onset. Moreover, some items included in the three ALSFRS-R subscales showed a problematic fit to the respective construct they were intended to measure. In conclusion, the interpretation of a total raw score of ALSFRS-R is hampered by ambiguities due to the different metric properties of the three domains the scale aggregates, and their content and structure. This study confirms that a refinement of ALSFRS-R is warranted, pointing to the need to revise its whole structure, and providing detailed guidelines for its revision.

Entities:  

Keywords:  ALSFRS-R; Amyotrophic lateral sclerosis; Rasch analysis; population based study

Mesh:

Year:  2015        PMID: 25916346     DOI: 10.3109/21678421.2015.1026829

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  20 in total

1.  Riluzole and other prognostic factors in ALS: a population-based registry study in Italy.

Authors:  Jessica Mandrioli; Sara Angela Malerba; Ettore Beghi; Nicola Fini; Antonio Fasano; Elisabetta Zucchi; Silvia De Pasqua; Carlo Guidi; Emilio Terlizzi; Elisabetta Sette; Alessandro Ravasio; Mario Casmiro; Fabrizio Salvi; Rocco Liguori; Lucia Zinno; Yasmin Handouk; Romana Rizzi; Annamaria Borghi; Rita Rinaldi; Doriana Medici; Mario Santangelo; Enrico Granieri; Vittoria Mussuto; Marina Aiello; Salvatore Ferro; Marco Vinceti
Journal:  J Neurol       Date:  2018-02-05       Impact factor: 4.849

2.  Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis.

Authors:  Jinsy A Andrews; Lisa Meng; Sarah F Kulke; Stacy A Rudnicki; Andrew A Wolff; Michael E Bozik; Fady I Malik; Jeremy M Shefner
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

3.  Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy.

Authors:  Jessica Mandrioli; Sara Biguzzi; Carlo Guidi; Elisabetta Sette; Emilio Terlizzi; Alessandro Ravasio; Mario Casmiro; Fabrizio Salvi; Rocco Liguori; Romana Rizzi; Vladimiro Pietrini; Annamaria Borghi; Rita Rinaldi; Nicola Fini; Elisabetta Chierici; Mario Santangelo; Enrico Granieri; Vittoria Mussuto; Silvia De Pasqua; Eleni Georgoulopoulou; Antonio Fasano; Salvatore Ferro; Roberto D'Alessandro
Journal:  Neurol Sci       Date:  2015-07-24       Impact factor: 3.307

Review 4.  Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design.

Authors:  Christina N Fournier
Journal:  Neurotherapeutics       Date:  2022-07-11       Impact factor: 6.088

5.  Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF).

Authors:  Ruben P A van Eijk; L H van den Berg; Ying Lu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-12-17       Impact factor: 13.654

6.  The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset.

Authors:  Malcolm Proudfoot; Ashley Jones; Kevin Talbot; Ammar Al-Chalabi; Martin R Turner
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-02-11       Impact factor: 4.092

7.  Increased Expressions of Plasma Galectin-3 in Patients with Amyotrophic Lateral Sclerosis.

Authors:  Jun Yan; Yun Xu; Li Zhang; Hui Zhao; Ling Jin; Wei-Guo Liu; Lei-Hua Weng; Zuo-Han Li; Ling Chen
Journal:  Chin Med J (Engl)       Date:  2016-12-05       Impact factor: 2.628

8.  Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model.

Authors:  Leonhard A Bakker; Carin D Schröder; Michael A van Es; Paul Westers; Johanna M A Visser-Meily; Leonard H van den Berg
Journal:  J Neurol       Date:  2017-06-12       Impact factor: 4.849

Review 9.  Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures.

Authors:  Thomas Morel; Stefan J Cano
Journal:  Orphanet J Rare Dis       Date:  2017-11-02       Impact factor: 4.123

10.  Do Generic Preference-Based Measures Accurately Capture Areas of Health-Related Quality of Life Important to Individuals with Amyotrophic Lateral Sclerosis: A Content Validation Study.

Authors:  Nicole Peters; Vanina Dal Bello-Haas; Tara Packham; Marvin Chum; Colleen O'Connell; Wendy S Johnston; Joy C MacDermid; John Turnbull; Jill Van Damme; Ayse Kuspinar
Journal:  Patient Relat Outcome Meas       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.